Page 1

Senzymatica INTERIM REPORT FOR ENZYMATICA AB ( PUBL ) JANUARY - JUNE 2021 Continued lower sales due to pandemic but some stabilization Q2 H1 ■ Net sales reached SEK 6.1 ( 13.9 ) million . • Net sales totaled SEK 23.1 ( 40.7 ) million . " Result after tax came in at SEK -19.7 ( -11.7 ) million . ■ Result after tax came in at SEK -28.5 ( -11.0 ) million . ■ ■ Earnings per share , basic and diluted , were SEK - 0.14 ( -0.08 ) . Cash and cash equivalents were SEK 64.8 ( 30.9 ) million . Significant events in Q1 ■ " " " Enzymatica's sales in the quarter decreased compared with Q2 2020 because of the pandemic resulting in fewer common colds . However , the cold remedy market in Sweden and in other markets began to recover during the quarter . Enzymatica's rights issue was completed on June 2nd and the company raised SEK 59.1 million before issue expenses . The issue was fully subscribed and underwritten by the company's three largest shareholders . The Japanese Patent Office granted Enzymatica's patent for the cod enzyme , which is one of the key components in the mouth spray ColdZymeⓇ , for the Japanese market . The patent is valid until 2036 . Enzymatica announced that the company is launching ColdZyme on Amazon in Sweden and the UK , which will improve consumer access to the product and generate increased exposure of the brand . Charlotte Andersson was appointed new Director Quality Assurance and Stefan Olsson Head of Corporate Communications . " Earnings per share , basic and diluted , were SEK -0.20 ( -0.08 ) . Significants events after the quarter On July 12 Enzymatica announced that the company has licensed exclusive rights to its German partner STADA to market and sell Viru Protect® ( ColdZyme ) in Vietnam . The Vietnamese self - care market is estimated to about EUR 2 billion and the Ear - Nose - Throat category to about EUR 20 million . On July 13 Enzymatica announced that the Board of Directors has appointed Claus Egstrand , the company's current Chief Operating Officer , to new CEO for Enzymatica . He assumes the new position at the latest on January 1 , 2022. Claus Egstrand replaces Therese Filmersson , who has been acting CEO since June 2020 , and who will return to the role as CFO . Impact of the coronavirus pandemic As a result of the coronavirus pandemic , with social distancing , improved hand hygiene and fewer social contacts , the cold remedy market in Sweden and internationally was down by 50 percent during the first quarter , but the markets began to stabilize during the second quarter . Enzymatica believes that the cold remedy markets will continue to recover in H2 2021 when the vaccination campaigns in the various countries are expected to be completed , primarily at the start of the cold season in the fourth quarter . The company does not see any direct other effects of COVID - 19 on the business with respect to production , logistics , sickness absence , etc. Financial ratios ( SEK THOUSAND ) Q2 2021 Q2 H1 H1 2020 2021 2020 Full year 2020 Net sales 6.1 13.9 23.1 40.7 111.2 Gross margin , % 29 58 47 71 68 Operating profit / loss -20.0 -11.9 -28.7 -11.7 -12.1 Cash flow from operating activities -14.4 -1.3 -13.1 -5.8 -10.7 Average number of employees 24 18 24 18 18 ENZYMATICA INTERIM REPORT JANUARY - JUNE 2021 | 1